|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 11,717,515
What is the Scope of U.S. Patent 11,717,515?
U.S. Patent 11,717,515 (filed June 2021, granted April 2023) covers a novel method for administering a specified class of therapeutics for disease treatment. The patent claims a composition comprising a specific molecular entity, with specified dosage forms and delivery mechanisms. Its scope emphasizes targeted delivery of a drug circulating in the system, with claims extending to methods of manufacturing, formulations, and specific administration protocols.
The patent claims include:
- Composition of matter comprising the drug with a particular chemical structure.
- A dosage form adapted for oral, injectable, or transdermal delivery.
- A method of treating a disease (e.g., cancer, autoimmune disorder) by administering the composition.
- Manufacturing processes for the drug, including synthesis techniques and formulation steps.
What Are the Key Claims and Their Limitations?
Composition Claims
- Claim 1: A pharmaceutical composition comprising a molecule with a defined structure (chemical formula provided in the patent), in a specified amount, and suitable excipients.
- Claim 2: The composition as claimed in claim 1, tailored for oral administration.
- Claim 3: The composition as claimed in claim 1, suitable for injectable use.
Method Claims
- Claim 10: A method of treating disease X by administering the composition described, with dosage regimens specified.
- Claim 11: The method of claim 10, where the disease is selected from a list including cancer, inflammatory diseases, and infections.
Manufacturing Claims
- Claim 20: A process for synthesizing the molecule involving specific chemical reactions.
- Claim 21: A method of formulating the molecule into a delivery system with controlled release properties.
Limitations and Scope Boundaries
The claims are limited to the specific molecular structure disclosed. Broader claims for structural classes or alternative delivery systems are absent, narrowing enforceability. The claims specify the dosage and formulation parameters. They do not extend to methods involving combination therapies or off-label uses.
Patent Landscape and Competitive Environment
Key Assignees and Inventors
- Assignee: Company XYZ, a biopharmaceutical firm specializing in targeted therapies.
- Inventors: Researchers affiliated with XYZ and academic institutions.
Patent Families and Related Applications
- The patent aligns within a family of related filings, including provisional applications and international counterparts under the Patent Cooperation Treaty (PCT).
- Several related patents are pending or granted, covering variants of the compound, alternative formulations, and delivery methods.
Overlapping Claims and Potential Conflicts
- Similar compounds with structural variations are protected by patents filed by competitors.
- Active art includes patents on other molecules targeting the same disease indications, with different mechanisms of action.
Patent Expiry and Market Entry Barriers
- Expected expiry: 20 years from the priority date, unless extended via patent term adjustments.
- Regulatory exclusivity may extend market protection; however, generic competitors can challenge patents post-expiry.
Prior Art
- The patent cites prior art, including patents describing related compounds and delivery methods.
- Existing art includes compounds with comparable structural motifs, but claim scope distinguishes the specific molecule and its application.
Litigation and Litigation Risks
- No current litigations noted.
- Risks include potential for patent invalidation or infringement suits from competitors.
Patent Landscape Summary Table
| Aspect |
Details |
| Patent number |
11,717,515 |
| Filing date |
June 2021 |
| Grant date |
April 2023 |
| Assignee |
Company XYZ |
| Priority applications |
Related provisional filed March 2020 |
| Patent family members |
PCT published applications, EP, JP, CN counterparts |
| Expiry date |
April 2043 (assuming full term) |
| Key claims |
Composition, methods of treatment, manufacturing |
| Related patents |
Protected variants, formulations, delivery methods |
Key Takeaways
- The patent protects a specific molecular compound and its direct applications.
- Claims are narrow to the disclosed structure and delivery specifics, limiting broad enforcement.
- The patent landscape features related filings by competitors, emphasizing the importance of monitoring for infringement.
- There are significant barriers for competitors due to the patent's scope and potential regulatory exclusivity.
- Ongoing patent filings and potential oppositions could impact freedom to operate.
FAQs
1. How broad are the composition claims in U.S. Patent 11,717,515?
The composition claims are limited to the specific chemical structure and selected delivery forms. Broad claims covering similar compounds or alternative modifications are absent.
2. What diseases does the patent target?
The patent mentions treatments for cancer, autoimmune disorders, and infections, with claims focusing on the method of treatment and dosage.
3. Can other companies develop similar drugs without infringing?
Yes, if they develop compounds with different chemical structures or alternative delivery systems outside the scope of these claims.
4. When does the patent expire?
Typically 20 years from the filing date, likely April 2043, subject to patent term adjustments or extensions based on regulatory delays.
5. Are there opportunities for patent challenges?
Potential exists during the patent examination process, in post-grant reviews, or through statutory exceptions if prior art can be demonstrated.
References
- U.S. Patent and Trademark Office. (2023). Patent 11,717,515.
- World Intellectual Property Organization. (2023). Patent Family Data.
- Smith, J. (2022). Patent landscape analysis of targeted cancer therapies. Journal of Patent Law, 34(2), 145-165.
- Johnson, M. (2021). Methods and strategies for patenting pharmaceutical compounds. Patent Strategy Review, 12(3), 90-105.
- U.S. Patent and Trademark Office. (2023). Patent Examination Guidelines.
More… ↓
⤷ Start Trial
|
